Association of anticoagulant use with clinical outcomes from crizotinib in ALK‐ and ROS1‐rearranged advanced non‐small cell lung cancers: A retrospective analysis of PROFILE 1001

Association of anticoagulant use with clinical outcomes from crizotinib in ALK‐ and ROS1‐rearranged advanced non‐small cell lung cancers: A retrospective analysis of PROFILE 1001

Abstract Background ROS1‐ and ALK‐rearranged advanced NSCLCs are associated with increased thromboembolic risk. We hypothesized that a prothrombotic phenotype offers an evolutionary advantage to subsets of these cancers. The impact of this phenotype could alter outcomes from targeted therapy. Method...

Full description

Bibliographic Details
Main Authors: Terry L. Ng, David C. C. Tsui, Sherry Wang, Tiziana Usari, Tejas Patil, Keith Wilner, David R. Camidge
Format: Article
Language:English
Published: Wiley 2022-12-01
Series:Cancer Medicine
Subjects:
ALK
crizotinib
lung cancer
ROS1
thromboembolism
Online Access:https://doi.org/10.1002/cam4.4789

Similar Items

Similar Items